Talentmark was engaged to work with the Chairman of the board, Andy Sandham, in a highly focused international search to find a CEO with a very specialised combination of scientific and commercial skills and experiences that could lead the company through its next evolutionary stage.
Bicycle Therapeutics is a biotechnology company developing a platform technology that enables the creation of a new generation of biotherapeutics combining the desirable features of small molecules and biopharmaceuticals to create highly specific and highly stable drugs. The company is a spin-out from the Medical Research Council Laboratory of Molecular Biology in Cambridge, based on the pioneering work of founding scientists Sir Gregory Winter and Dr.Christian Heinis.
The company had reached the position where it had built a sound technical base but needed to make some key decisions on its development path to a planned exit. The strategy for the CEO would include careful selection of drug discovery projects and developing targets for corporate deals with strategic partners.
It was always going to be challenging to find one individual with previous functional experience as a CSO , CMO and CEO in a company with a similar technology and business challenges. Talentmark also needed to find someone with the right personal qualities to lead the scientific team and board.
After considerable research, Talentmark identified that Dr Rolf Guenther was a potential candidate and this led on to his successful appointment.